Recently, KGF has also been recognized for its protective effect on normal epithelial tissues, and use of recombinant KGF has been approved for prevention and treatment of severe oral mucositis in patients with hematologic cancers receiving high-dose chemotherapy and radiation therapy followed by bone marrow transplantation. The gene discussed is FGF7; the disease is oral mucositis.